Welcome to our dedicated page for United Guardian news (Ticker: UG), a resource for investors and traders seeking the latest updates and insights on United Guardian stock.
United-Guardian, Inc. manufactures specialty ingredients and healthcare products across cosmetic ingredients, personal care and sexual wellness ingredients, pharmaceuticals, and medical lubricants. Company updates commonly cover quarterly and annual operating results, product-category sales trends, cash dividends, and demand for Renacidin, its key pharmaceutical product.
United-Guardian news also discusses distributor activity for cosmetic ingredients, including purchasing patterns at Ashland Specialty Ingredients, international demand conditions, tariff-related pressures, medical lubricant sales, product-development efforts for personal care markets, and board governance updates.
United-Guardian, Inc. (NASDAQ: UG) declared a cash dividend of $0.42 per share, to be paid on June 17, 2020, to stockholders of record on June 3, 2020. This marks the 25th consecutive year of dividend payments. President Ken Globus highlighted the company’s ability to maintain production and strong sales during the Covid-19 pandemic, although he noted potential temporary declines in sales ahead. The Board expressed optimism about future performance, especially in pharmaceutical and cosmetic segments.
United-Guardian, Inc. (NASDAQ: UG) reported a 4% increase in net sales for Q1 2020, totaling $3,322,914 compared to $3,180,318 in Q1 2019. However, net income fell sharply to $790,307 ($0.17 per share) from $1,222,694 ($0.27 per share) in the prior year, primarily due to declines in marketable securities. The company maintained operations as an essential business during the pandemic, with strong sales in April. President Ken Globus noted potential future declines in cosmetic ingredient sales but expressed optimism for pharmaceuticals and medical products.